High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial - The Lancet
Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma - ScienceDirect
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia
Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells
Flowchart of regimen consisting of cladribine, cytarabine and etoposide... | Download Scientific Diagram
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483) | Leukemia
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia
![PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7550a5cdc69f479a7aec573d63770ee1c9f77045/6-Figure2-1.png "PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar")
PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar
Hematologic Malignancies - ppt download
How I treat older patients with acute myeloid leukemia
AML Hub on Twitter: "CONGRESS | #ASCO20| Andrew Wei, @MonashUni, presents an update on venetoclax ➕ low-dose cytarabine in previously untreated older patients with #AML. Median OS was higher with venetoclax +
![PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7550a5cdc69f479a7aec573d63770ee1c9f77045/5-Figure1-1.png "PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar")
PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients - ScienceDirect
Pan‑RAF inhibitor LY3009120 is highly synergistic with low‑dose cytarabine, but not azacitidine, in acute myeloid leukemia with <em>RAS</em> mutations
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia - ScienceDirect
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy | Journal of Hematology & Oncology | Full Text
PDF) Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study
Control CBC after 3 months of low dose ARA-C. | Download Scientific Diagram
ASH 2022: A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
Overall survival of glasdegib in combination with low-dose cytarabine, | CEOR
Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low -dose cytarabine and placebo in older adults with untreated acute myeloid leukemia | Haematologica
Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells
Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML - Figure f6 | Aging
